A polysomnographic study was conducted on 10 outpatients with major de
pression at baseline and during 4 to 8 weeks of open-trial treatment w
ith nefazodone (400 to 600 mg/day). All 10 patients were treatment res
ponders as evidenced by at least 50% reduction from baseline scores on
the Hamilton Depression Rating Scale. Nefazodone was associated with
significantly decreased wake and movement time and increased minutes a
nd percentage of stage 2 sleep at the expense of right stage 1 sleep.
Nefazodone did not increase rapid-eye-movement (REM) latency anti it d
id not suppress REM sleep. In fact, a trend toward increased REM in th
e second REM period was observed, although decreased REM in the third
REM period was also noted. In summary, nefazodone, an effective antide
pressant, decreases arousals and wakefulness during sleep and reduces
light non-REM sleep. This agent does not appear to suppress REM sleep
or prolong REM latency in patients who respond to treatment.